Prednisone with or without IVIg for ITP in pregnancy
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial compares two treatments for pregnant women with ITP (immune thrombocytopenia) and low platelet counts. It tests whether adding IVIg (immune globulin) to standard prednisone (steroid) therapy is more effective than prednisone alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 50 years old.
- You have been diagnosed with immune thrombocytopenia (ITP) and are pregnant.
- You have not received any ITP treatment during this pregnancy.
- You are at least 12 weeks pregnant.
- Your platelet count is below 30 (thousand per microliter).
- You do not have certain other autoimmune diseases, infections, or severe organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of upadacitinib (a pill that calms the immune system) and high-dose dexamethasone (a steroid) as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this mix can safely raise platelet counts better than steroids alone.
This trial studies a short, high-dose steroid plan (prednisone plus dexamethasone) to treat immune thrombocytopenia (ITP) in children and raise low platelet counts. It may help reduce bleeding risk while using an approach tested in children soon after diagnosis.
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests a combination of two common medicines (atorvastatin and NAC) plus romiplostim to treat ITP when steroids have stopped working or stopped working. It may help raise your platelet counts.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.